Muir-3
Posted Date: Mar 5, 2025
- Investigator: Dylan Steen
- Specialties:
- Type of Study: Drug
This study investigates plozasiran (ARO-APOC3) as a potential treatment for hypertriglyceridemia in adults. Severe hypertriglyceridemia is characterized by extremely high levels of triglycerides in the blood, which can lead to cardiovascular diseases. Participants will randomized 3:1 to plozasiran or placebo injections every 3 months over a year. The primary outcome is the percent change in fasting serum triglyceride levels from baseline to month 12. Secondary outcomes include changes in fasting triglyceride levels, adverse events, and diabetes-related measures. The study aims to determine plozasiran's effectiveness in reducing triglyceride levels.
Criteria:
Established Diagnosis Of Hypertriglyceridemia And Prior Documented Evidence Of Mean Fasting Tg Level =150 Mg/Dl
Keywords:
Plozasiran For Triglycerides =150 Mg/Dl
For More Information:
Harshada More
5135584739
morehp@ucmail.uc.edu